Ophthalmic nsaids as adjuvants

An ophthalmic and adjuvant technology, applied to medical preparations containing active ingredients, anti-inflammatory agents, non-central analgesics, etc.

Inactive Publication Date: 2011-02-02
EASTA PHARMA +1
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, intravitreal injections can pose a degree of risk and / or discomfort to the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic nsaids as adjuvants
  • Ophthalmic nsaids as adjuvants
  • Ophthalmic nsaids as adjuvants

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0168] Example 1: Combination Approach Using NSAIDs and Antiangiogenic Therapy in the Treatment of Ocular Angiogenic Diseases

[0169] Recent data in a mouse model of retinal neovascular disease showed a beneficial effect of bromfenac ophthalmic solution when administered topically to mice with laser-induced angiomatous retina. like figure 1 As shown in , the antiangiogenic effect produced by bromfenac was greater than that obtained using intravitreal administration of soluble VEGF receptors. figure 1 showed inhibition of choroidal neovascularization (CNV) lesions after 2 weeks of topical administration of 0.1% bromfenac ophthalmic solution (BF) to mice with CNV induced by laser photocoagulation; and 0.1% BF vs. Effects of Vascular Endothelial Growth Factor (VEGF) Neutralizing Protein, Recombinant Murine Soluble Receptor 1 / Fc Chimeric Protein (sVEGFR-1 / Fc). This study showed that the area of ​​choroidal neovascularization was reduced by 71% with bromfenac treatment compare...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application No. 61 / 030,464, filed February 21, 2008, which is hereby incorporated by reference in its entirety for all purposes. Background of the invention [0003] Macular degeneration is an incurable eye disease and a leading cause of blindness that affects more than 10 million people age 55 and older in the United States. The disease is caused by the deterioration of the macula, the central part of the retina located in the inner layer of the eye that focuses, records and transmits images from the eye to the brain via the optic nerve. As people age, their chances of developing eye diseases increase dramatically. The specific factors that cause macular degeneration cannot be determined, but research in this area is gradually increasing. [0004] There are two basic types of macular degeneration: the "wet" (exudative) type and the "dry" (atrophic) type. A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/196A61K39/395A61P27/02
CPCA61K31/196A61P27/00A61P27/02A61P29/00
Inventor 蒂姆·麦克纳马拉西蒙·P·钱德勒喜田彻郎
Owner EASTA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap